Citations

Clear

299 citation(s) found for "Solomon, B".

Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren’s Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study
Ben‐Eli, Hadas , Aframian, Doron J. , Ben‐Chetrit, Eldad , Mevorach, Dror , Kleinstern, Geffen , Paltiel, Ora , Solomon, Abraham

Mayo Clinic

Journal of Immunology Research | January 21, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-9

10.1155/2019/9060842 | PMID 30805374 Get It

Objectives. To assess whether there are shared exposures associated with Sjogren’s syndrome (SS), dry eye syndrome (DES), and B-cell non-Hodgkin lymphoma (B-NHL), in order to determine whether they are etiologically related. Methods. In a clinic-based case-control study, 702 participants (91 SS, 120 DES, 211 (age and sex frequency-matched) controls, and 280 B-NHL cases) were recruited and interviewed regarding exposures, medical history, and family history. Results. Female predominance was noted in SS (ratio 9.2 : 1). Eye dryness was severest in SS compared to DES and controls (P<0.001). Compared to controls, alcohol consumption was inversely associated with NHL, DES, and SS (odds ratio OR=0.47, 95% confidence interval (CI): 0.31-0.71; OR=0.54, 95% CI: 0.33-0.88; and OR=0.26, 95% CI: 0.14-0.49, respectively), while a previous history of infection requiring hospitalization was positively associated with all three conditions: NHL (OR=1.92; 95% CI: 1.23-2.99), DES (OR=3.29; 95% CI: 1.97-5.47), and SS (OR=4.74; 95% CI: 2.66-8.44). NHL patients were more likely to report first-degree relatives with hematologic cancer, while having first-degree relatives with an autoimmune disease (AID) was associated with SS (OR=5.25; 95% CI: 2.59-10.63) and DES (OR=3.55; 95% CI: 1.83-6.91) compared to controls. Conclusions. Some exposures are associated with all three conditions (such as an inverse association with alcohol consumption and a positive association with serious past infection), while a family history of AID appears to be shared by DES and SS, but not NHL subjects. Shared risk factors for all three conditions indicate possible mutual etiological pathways.
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Solomon, Scott D. , Adams, David , Kristen, Arnt V. , Grogan, Martha , Maurer, Mathew S. , Merlini, Giampaolo , Slama, Michel , Brannagan, Thomas H., Shah, Amil M. , Garg, Pushkal, Vaishnaw, Akshay, Karsten, Verena, Gollob, Jared , Vest, John, Merlini, Giampaolo , Brannagan, T H , Adams, David , Shah, Amil , Solomon, Scott David , González-Duarte, Alejandra , Maurer, Mathew S , Damy, Thibaud , Dispenzieri, Angela , Berk, John L. , Chen, Jihong , Vest, John, Suhr, Ole B.

Mayo Clinic

Circulation | January 17, 2019 | Volume: 139 | Issue: 4 | Pages: 431-443

10.1161/circulationaha.118.035831 | PMID 30586695 Get It

Background: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The APOLLO study assessed the efficacy and tolerability of patisiran in patients with hATTR amyloidosis. The effects of patisiran on cardiac structure and function in a prespecified subpopulation of patients with evidence of cardiac amyloid involvement at baseline were assessed. Methods: APOLLO was an international, randomized, double-blind, placebo-controlled phase 3 trial in patients with hATTR amyloidosis. Patients were randomized 2:1 to receive 0.3 mg/kg patisiran or placebo via intravenous infusion once every 3 weeks for 18 months. The prespecified cardiac subpopulation comprised patients with a baseline left ventricular wall thickness ≥13 mm and no history of hypertension or aortic valve disease. Prespecified exploratory cardiac end points included mean left ventricular wall thickness, global longitudinal strain, and N -terminal prohormone of brain natriuretic peptide. Cardiac parameters in the overall APOLLO patient population were also evaluated. A composite end point of cardiac hospitalizations and all-cause mortality was assessed in a post hoc analysis. Results: In the cardiac subpopulation (n=126; 56% of total population), patisiran reduced mean left ventricular wall thickness (least-squares mean difference ± SEM: –0.9±0.4 mm, P =0.017), interventricular septal wall thickness, posterior wall thickness, and relative wall thickness at month 18 compared with placebo. Patisiran also led to increased end-diastolic volume (8.3±3.9 mL, P =0.036), decreased global longitudinal strain (–1.4±0.6%, P =0.015), and increased cardiac output (0.38±0.19 L/min, P =0.044) compared with placebo at month 18. Patisiran lowered N -terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 months, ratio of fold-change patisiran/placebo 0.45, P <0.001). A consistent effect on N -terminal prohormone of brain natriuretic peptide at 18 months was observed in the overall APOLLO patient population (n=225). Median follow-up duration was 18.7 months. The exposure-adjusted rates of cardiac hospitalizations and all-cause death were 18.7 and 10.1 per 100 patient-years in the placebo and patisiran groups, respectively (Andersen–Gill hazard ratio, 0.54; 95% CI, 0.28–1.01). Conclusions: Patisiran decreased mean left ventricular wall thickness, global longitudinal strain, N -terminal prohormone of brain natriuretic peptide, and adverse cardiac outcomes compared with placebo at month 18, suggesting that patisiran may halt or reverse the progression of the cardiac manifestations of hATTR amyloidosis. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01960348.
Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Lewis, Karl D. , Sekulić, Aleksandar , Migden, Michael R. , Oro, Anthony E. , LoRusso, Patricia , Hainsworth, John D. , Williams, Sarah, Hou, Jeannie , Hoff, Daniel D. Von , Hauschild, Axel , Rudin, Charles M. , Dirix, Luc , Solomon, James A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9012-9012

10.1200/jco.2014.32.15_suppl.9012 Get It

CRTC1–MAML2 fusion in mucoepidermoid carcinoma of the breast
Bean, Gregory R. , Krings, Gregor , Otis, Christopher N. , Solomon, David A. , García, Joaquín J. , Zante, Annemieke van , Camelo‐Piragua, Sandra , Ziffle, Jessica Van , Chen, Yunn‐Yi, Solomon, David A , Chen, Yunn-Yi

Mayo Clinic

Histopathology | October 31, 2018 | Volume: 74 | Issue: 3 | Pages: 463-473

10.1111/his.13779 | PMID 30380176 Get It

AimsMucoepidermoid carcinomas (MEC) are the most common malignant neoplasms of salivary glands, but are uncommon in other sites. Salivary gland MEC are most frequently associated with CRTC1–MAML2 translocations. Exceedingly rare MEC of the breast demonstrate a basal‐like and often triple (oestrogen and progesterone receptor, HER2)‐negative immunophenotype, with a single case previously reported to show MAML2 rearrangement, although the fusion partner was not known. Comprehensive genomic studies of breast MEC are lacking. In this study, we analysed the immunophenotype and molecular landscape of two breast MEC to elucidate the pathogenesis of these rare tumours.Methods and resultsTwo breast MEC were subjected to capture‐based next‐generation DNA sequencing of 479 cancer‐related genes. The presence of the CRTC1–MAML2 fusion transcript was interrogated by reverse transcriptase–polymerase chain reaction. In addition, the immunoprofiles of breast MEC were compared to salivary gland MEC. Both breast MEC harboured CRTC1–MAML2 fusions. In contrast to most triple‐negative breast carcinomas of no special type, the mutational burden of MEC was very low, with one case demonstrating only an inactivating SETD2 mutation, and the other harbouring no somatic variants in genes on the panel. No copy number alterations were identified. The immunoprofiles of breast and salivary gland MEC were overlapping, but not identical.ConclusionsThe findings highlight MEC as a breast cancer subtype more closely related to its salivary gland counterpart than to basal‐like/triple‐negative breast cancers of no special type.
Abstract 242: Large pathway and gene set analysis of GWAS data identifies novel associations for pancreatic cancer
Zhang, Han , Hyland, Paula L. , Yang, Qi , Childs, Erica J., Hartge, Patricia, Hoover, Robert N. , Li, Donghui , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Walsh, Naomi , Mocci, Evelina , Zhang, Mingfeng , Wang, Zhaoming , Chanock, Stephen Jacob , Kraft, Peter , Risch, Harvey A. , Ámundadóttir, Laufey T. , Yu, Herbert , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 242-242

10.1158/1538-7445.am2018-242 Get It

Abstract Objective Genome-wide association studies (GWAS) identify associations of individual SNPs with cancer risk but usually only explain a fraction of the inherited variability. Pathway analysis of genetic variants has been shown for many disorders to be a powerful tool in discovering novel networks of susceptibility genes. Design We have conducted a large agnostic pathway-based meta-analysis of GWAS data using the summary-based adaptive rank truncated product (sARTP) method to identify novel gene sets and pathways associated with pancreatic ductal adenocarcinoma (PDA) in 9,040 cases and 12,495 controls. We performed expression quantitative trait loci (eQTL) analysis and functional annotation of the top SNPs in genes identified in PDA-associated gene sets and pathways. Results We identified 14 gene sets and pathways associated with PDA at FDR &lt; 0.05. Five of the strongest signals (P-value ≤ 1.3x10-5 Bonferroni corrected) were in genes from KEGG maturity onset diabetes of the young, Reactome regulation of beta cell development, Biocarta role of epidermal growth factor (EGF) receptor transactivation by G-protein-coupled receptors in cardiac hypertrophy pathway, Nikolsky breast cancer chr17q11-q21 amplicon gene set, and Pujana ATM Pearson correlation coefficient (PCC) network gene set. We identified and validated rs876493 and three correlated SNPs (PGAP3) and rs3124737 (CASP7) as eQTLs in two normal derived pancreas tissue datasets. Conclusion Our agnostic gene set and pathway analysis integrated with functional annotation and eQTL analysis provides novel insight into genes and pathways that may be biologically relevant for risk of PDA. Citation Format: Naomi Walsh, Han Zhang, Paula L. Hyland, Qi Yang, Evelina Mocci, Mingfeng Zhang, Erica J. Childs, Zhaoming Wang, Stephen Chanock, Patricia Hartge, Robert Hoover, Peter Kraft, Donghui Li, Eric J. Jacobs, Gloria M. Petersen, Brian M. Wolpin, Harvey A. Risch, Laufey T. Amundadottir, Kai Yu, Alison P. Klein, Rachael Z. Stolzenberg-Solomon. Large pathway and gene set analysis of GWAS data identifies novel associations for pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 242.
Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer
Walsh, Naomi , Hyland, Paula L. , Yang, Qi , Childs, Erica J., Collins, Irene , Wang, Zhaoming , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Gallinger, Steven , Goodman, Gary E. , Goodman, Phyllis J. , Hung, Rayjean J, Kurtz, Robert C. , Scélo, Ghislaine , Shu, Xiao Ou , Visvanathan, Kala , consortia, PanScan and PanC4, Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Borgida, Ayelet , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Chaffee, Kari G. , Foretová, Lenka , Fuchs, Charles S. , Gaziano, J. Michael , Giovannucci, Edward, Hackert, Thilo , Haiman, Christopher A. , Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Herman, Joseph M. , Holly, Elizabeth A., Hoover, Robert N. , Hung, Rayjean J, Janout, Vladimí­r , Klein, Eric A. , Laheru, Daniel A. , Lee, I‐Min , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Strobel, Oliver , Thornquist, Mark, Wactawski‐Wende, Jean , Wareham, Nick, Weiderpass, Elisabete , Wentzensen, Nicolas , Wheeler, William, Zeleniuch‐Jacquotte, Anne , Kraft, Peter , Li, Donghui , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Rabe, Kari G. , Hung, Rayjean J. , Cleary, Sean, Weiderpass, Elisabete , Arslan, Alan A , Canzian, Federico , Hung, Rayjean J , Wactawski-Wende, Jean , Wang, Zhaoming , Visvanathan, Kala , Klein, Eric A , Strobel, Oliver , Kraft, Peter , Porta, Miquel , Real, Francisco X , Zeleniuch-Jacquotte, Anne , Zhang, Han , Mocci, Evelina , Zhang, Mingfeng , Freeman, Laura E. Beane , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Hung, Rayjean J, Kooperberg, Charles , Malats, Núria , Marchand, Loı̈c Le , Neale, Rachel Ε. , Olson, Sara H. , Van Den Eeden, Stephen K , White, Emily , Zheng, Wei , consortia, PanScan and PanC4, Albanes, Demetrius , Bamlet, William R. , Boutron‐Ruault, Marie‐Christine , Brais, Lauren K , Chanock, Stephen Jacob , Cleary, Sean P. , Cotterchio, Michelle , Holcátová, Ivana , Hung, Rayjean J, Lu, Lingeng , Männistö, Satu , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Wareham, Nick, Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Yu, Kai , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 15, 2018 | Volume: 111 | Issue: 6 | Pages: 557-567

10.1093/jnci/djy155 | PMID 30541042 Get It

A Survey of the Prevalence and Practice Patterns of Human Acellular Nerve Allograft Use
Azouz, Solomon M., Mahabir, Raman C. , Noland, Shelley S. , Lucas, Heather D, Lucas, Heather D.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | August 7, 2018 | Volume: 6 | Issue: 8 | Pages: e1803

10.1097/gox.0000000000001803 | PMID 30254826 Get It

Background: There have been many technical and scientific advances over the last decade in peripheral nerve surgery. Human acellular nerve graft (HANA) has become increasingly popular but current practice patterns among hand surgeons have yet to be defined. Coding practices may not have kept up with this innovation. A 26 question survey of hand surgeons was performed to evaluate the adoption of HANA, and current coding and billing practices. The survey was sent to hand surgeons trained in orthopedic, plastic, general, and neuro surgery. The survey was designed and implemented by the Mayo Clinic Survey Center. Results: Four hundred sixty-one responses to the survey were received. Most respondents currently use HANA (70%). Of those surgeons who do use HANA, nearly all use it less than 10 times per month (98%). There was no significant difference in the use of HANA across different specialties. There was a significant difference in HANA use depending on practice type with higher use by those in group private practice (57%) compared with academic practice (28%), solo practice (12%), and other practice environment (3%). There was a significant difference in HANA use depending on the number of years in practice. Those in practice less than 5 years used HANA the most (32%), followed by > 20 years in practice (27%), 6–10 years in practice (16%), 16–20 years in practice (14%), and 11–15 years in practice (11%). When asked the Current Procedural Terminology code they would use to bill for the procedure of choice, the most common response was 64910 (nerve repair with synthetic conduit or vein allograft). Conclusions: HANA has surpassed nerve conduit as the traditional gold standard in our study with nearly 70% of hand surgeons using HANA in their practice and a greater percentage of respondents choosing HANA as their first choice to repair as compared with nerve conduit, nerve autograft, or vein graft. There remains confusion regarding appropriate billing practices for the use of HANA. Due to its common use, a Current Procedural Terminology code should specifically designated for the use of HANA in the hand.
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Solomon, Scott D. , Rizkala, Adel R. , Lefkowitz, Martin, Shi, Victor , Gong, Jianjian , Anavekar, Nagesh S., Arango, Juan Luis, Arenas, J., Ben-Gal, T., Boytsov, S. А. , Chen, Chen-Huan, Cleland, John G.F. , DUENGEN, H, Echeverría, Luis Eduardo , Filippatos, Gerasimos , Flammer, Andreas J. , Galinier, Michel , Godoy, Armando, Gonçalvesová, Eva , Janssens, Stefan , Katova, Tzvetana, Køber, Lars , Lelonek, Małgorzata , Linssen, Gerard C.M. , Lund, Lars H. , O’Meara, Eileen , Perrone, Sergio V. , Ranjith, Naresh , Saito, Yoshihiko , Saraiva, Jose F. Kerr, Shah, Sanjiv J. , Seferović, Petar , Sibulo, Antonio S., Sim, David , Sweitzer, Nancy K. , Taurio, Jyrki , Vinereanu, Dragoş , Vrtovec, Bojan , Yılmaz, Mehmet Birhan , Zhou, Jingmin , Zweiker, Robert , Anand, Inder S. , Maggioni, Aldo P. , Pieske, Burkert , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Zile, Michael R. , McMurray, John J.V. , Felker, G. Michael , Zile, Michael R , Anand, Inder S , Maggioni, Aldo P , McMurray, John J V , Shah, Sanjiv J , Solomon, Scott David , Anker, Stefan D. , Atar, Dan , Chopra, Vijay , Comín‐Colet, Josep , Merkely, Béla , Miličić, Davor , Oh, Byung‐Hee , Senni, Michele , Sim, David , Jr., Jiri Widimsky , Ge, Junbo , Lam, Carolyn S.P. , Martínez‐Pastor, Felipe , Packer, Milton , Pfeffer, Marc Alan , Køber, Lars , Cleland, John G F

Mayo Clinic

Circulation: Heart Failure | July 6, 2018 | Volume: 11 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.118.004962 | PMID 29980595 Get It

Background: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality. Methods and Results: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 patients randomized in PARAGON-HF, grouped by factors that influence criteria for study inclusion. We further compared baseline characteristics of patients enrolled in PARAGON-HF with those patients enrolled in other recent trials of heart failure with preserved ejection fraction (HFpEF). Among patients enrolled from various regions (16% Asia-Pacific, 37% Central Europe, 7% Latin America, 12% North America, 28% Western Europe), the mean age of patients enrolled in PARAGON-HF was 72.7±8.4 years, 52% of patients were female, and mean left ventricular ejection fraction was 57.5%, similar to other trials of HFpEF. Most patients were in New York Heart Association class II, and 38% had ≥1 hospitalizations for heart failure within the previous 9 months. Diabetes mellitus (43%) and chronic kidney disease (47%) were more prevalent than in previous trials of HFpEF. Many patients were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (85%), β-blockers (80%), calcium channel blockers (36%), and mineralocorticoid receptor antagonists (24%). As specified in the protocol, virtually all patients were on diuretics, had elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (median, 911 pg/mL; interquartile range, 464–1610), and structural heart disease. Conclusions: PARAGON-HF represents a contemporary group of patients with HFpEF with similar age and sex distribution compared with prior HFpEF trials but higher prevalence of comorbidities. These findings provide insights into the impact of inclusion criteria on, and regional variation in, HFpEF patient characteristics. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01920711.
Perioperative Medication Management: Reconciling Differences across Clinical Sites
Duncan, Benjamin J. , Furniss, Stephanie K, Solomon, Andrew , Burton, Matthew M., Poterack, Karl A. , Miksch, Timothy, Helmers, Richard A. , Zheng, Lu , Doebbeling, Bradley N. , Grando, Adela , Kaufman, David Ross

Mayo Clinic

Proceedings of the International Symposium on Human Factors and Ergonomics in Health Care | June 29, 2018 | Volume: 7 | Issue: 1 | Pages: 44-51

10.1177/2327857918071010 Get It

Medication reconciliation (MedRec) is a mission-critical process which can serve to reduce adverse drug events (ADEs) in surgical settings. However, providing quality care is limited by current health information technology (IT), which is often inefficient and unintuitive due to poor usability, resulting in high cognitive burden. We have been characterizing EHR mediated workflow in the Mayo Clinic enterprise prior to a system-wide electronic health records (EHR) conversion in order to harmonize workflows. We compared and evaluated MedRec processes in pre-operative nursing assessments across two different EHRs in place in different locales at baseline. The interfaces differed both in their modes of interaction and cognitive support. Analyses surfaced interface elements that were unintuitive and inefficient, creating unnecessary complexities in clinicians’ interactive behavior. Keystroke level models (KLM), a modeling tool for predicting task completion time, showed that to access medication lists required a different series of operations across the two systems. Different designs can differentially mediate task performance, which can aid in the mitigation of errors for complex cognitive tasks. Identification of barriers in EHR-mediated workflow and barriers to interface usability could lead to system redesigns that minimize cognitive load while improving patient safety and efficiency.